# Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

> **NCT02401542** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rainier Therapeutics** · enrollment: 71 (actual)

## Conditions studied

- Locally Advanced or Metastatic Urothelial Cell Carcinoma
- Urinary Bladder Disease
- Urological Diseases

## Interventions

- **DRUG:** Vofatamab
- **DRUG:** Docetaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02401542
- **Lead sponsor:** Rainier Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2019-11-01
- **Final completion:** 2019-11-01
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** program has been put on hold by the sponsor
- **Last updated:** 2020-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02401542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02401542, "Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02401542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*